These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 15284857)
41. Association between type II cryoglobulinemia and hepatitis C virus in a case treated with interferon-alpha. Fukumoto S; Ishimura E; Shoji S; Izumotani T; Kitahashi S; Kuroki T; Nishizawa Y; Morii H Nephron; 1996; 73(1):94-6. PubMed ID: 8742965 [No Abstract] [Full Text] [Related]
42. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin's lymphoma treated with rituximab-containing regimens. Pellicelli AM; Zoli V Dig Liver Dis; 2011 Jun; 43(6):501-2. PubMed ID: 21459059 [No Abstract] [Full Text] [Related]
43. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Zylberberg H; Chaix ML; Bréchot C Ann Intern Med; 2000 May; 132(10):845-6. PubMed ID: 10819720 [No Abstract] [Full Text] [Related]
44. New hepatitis C therapies. Pawlotsky JM Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253 [No Abstract] [Full Text] [Related]
45. Hepatic hepatitis C virus RNA in chronic hepatitis C. Craxì A; Di Marco V; Almasio PL Ann Intern Med; 1996 Jan; 124(1 Pt 1):72. PubMed ID: 7503483 [No Abstract] [Full Text] [Related]
46. Diffuse large B-cell lymphoma in a hepatitis C virus-infected patient presenting with lactic acidosis and hypoglycemia. Keller BC; Nussensveig D; Dowell JE Am J Med Sci; 2010 Feb; 339(2):202-4. PubMed ID: 20087167 [TBL] [Abstract][Full Text] [Related]
47. Large granular lymphocyte leukemia associated with hepatitis C virus infection and B cell lymphoma: improvement after antiviral therapy. Poullot E; Bouscary D; Guyader D; Ghandour C; Roussel M; Fest T; Houot R; Lamy T Leuk Lymphoma; 2013 Aug; 54(8):1797-9. PubMed ID: 23176408 [No Abstract] [Full Text] [Related]
48. HCV infection and non-Hodgkin lymphomas: an evolving story. Defrancesco I; Zerbi C; Rattotti S; Merli M; Bruno R; Paulli M; Arcaini L Clin Exp Med; 2020 Aug; 20(3):321-328. PubMed ID: 32052244 [TBL] [Abstract][Full Text] [Related]
49. Current and future therapies for hepatitis C virus infection. Liang TJ; Ghany MG N Engl J Med; 2013 May; 368(20):1907-17. PubMed ID: 23675659 [TBL] [Abstract][Full Text] [Related]
50. Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Armor JF; Fazili J; Toubia N; Kern W; Kamble R; Kharfan-Dabaja MA Am J Hematol; 2005 Mar; 78(3):212-5. PubMed ID: 15726605 [TBL] [Abstract][Full Text] [Related]
51. [Progress and new challenges in hepatitis C]. Moradpour D; Frossard JL Rev Med Suisse; 2013 Sep; 9(396):1563-4. PubMed ID: 24066462 [No Abstract] [Full Text] [Related]
52. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Arcaini L; Merli M; Volpetti S; Rattotti S; Gotti M; Zaja F Clin Dev Immunol; 2012; 2012():638185. PubMed ID: 22956970 [TBL] [Abstract][Full Text] [Related]
53. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Frigeni M; Besson C; Visco C; Fontaine H; Goldaniga M; Visentini M; Pulsoni A; Torres HA; Peveling-Oberhag J; Rossotti R; Zaja F; Rigacci L; Merli M; Dorival C; Alric C; Piazza F; Gentile M; Ferrari A; Pirisi M; Nassi L; Rattotti S; Frustaci A; Milella M; Cencini E; Defrancesco I; Ferretti VV; Bruno R; Hermine O; Arcaini L Leukemia; 2020 May; 34(5):1462-1466. PubMed ID: 31836855 [No Abstract] [Full Text] [Related]
54. Hepatitis C virus infection and MALT-type ocular adnexal lymphoma. Arnaud P; Escande MC; Lecuit M; Validire P; Levy C; Plancher C; Vincent-Salomon A; Brousse N; de Cremoux P; Hermine O; Decaudin D Ann Oncol; 2007 Feb; 18(2):400-1; author reply 401-3. PubMed ID: 17065589 [No Abstract] [Full Text] [Related]
55. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. Rubbia-Brandt L; Giostra E; Mentha G; Quadri R; Negro F J Hepatol; 2001 Aug; 35(2):307. PubMed ID: 11580157 [No Abstract] [Full Text] [Related]
56. Hepatitis C virus infection in patients with B-cell lymphoproliferative disorders. Guida M; D'Elia G; Benvestito S; Casamassima A; Micelli G; Quaranta M; Moschetta R; De Lena M; Lorusso V Leukemia; 2002 Oct; 16(10):2162-3. PubMed ID: 12357374 [No Abstract] [Full Text] [Related]
57. Experimental Study of Flakozid Activity in Viral Hepatitis C In Vitro. Fateeva TV; Deryabin PG; Bortnikova VV; Krepkova LV; Mizina PG Bull Exp Biol Med; 2019 Aug; 167(4):479-481. PubMed ID: 31502123 [TBL] [Abstract][Full Text] [Related]
58. Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number. Yoshida EM; Dar Santos A; Partovi N; Ford JA Can J Gastroenterol; 2006 Aug; 20(8):519-20. PubMed ID: 16967572 [No Abstract] [Full Text] [Related]
59. Hepatitis C in 2006. Williams R Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):309-11. PubMed ID: 16538099 [No Abstract] [Full Text] [Related]
60. B cell malignancy and hepatitis C virus infection. Izumi T; Sasaki R; Miura Y; Okamoto H Leuk Res; 1996 May; 20(5):445. PubMed ID: 8683985 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]